Linzagolix not checked

Kissei Pharmaceutical Co., Ltd. · OBE2109 · KLH-2109

FollowEvery change as it happens, and a Monday email
Stage
in the EU
Next date
Phase 3 trial completes
Trials
2 active
11 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“\- KLH-2109 tablet: Oral administration \- Leuprorelin acetate placebo: Subcutaneous administration”In the company’s words, NCT07015268 on ClinicalTrials.gov
Tested for
Endometriosis
Main trialPhase 3
“To verify the non-inferiority of KLH-2109 to leuprorelin acetate in a double-blind manner in terms of efficacy in endometriosis patients with pelvic pain.”In the company’s words, NCT07015268 on ClinicalTrials.gov
Other names
OBE2109 · KLH-2109

Other drugs for Endometriosis

All 8 drugs for Endometriosis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Nov 2027 A Clinical Study of KLH-2109 in Patients With Endometriosis
Phase 3Completed 16 Sep 2019 Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase 3Completed 14 Apr 2020 Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Phase 3Terminated 6 Jan 2021 A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
Phase 3Terminated 8 Jan 2021 Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
Phase 3Completed 18 Oct 2021 Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.
Phase 3Completed 15 Sep 2022 Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)
Phase 3Completed 16 Feb 2024 A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain
Phase 3Completed 21 Aug 2024 A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
Phase 2Completed Apr 2018 A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
Phase 2Authorised not given Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Linzagolix

Following is part of Solo: you see every change to Linzagolix the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in